Biotech catalysts
Public drugmakers ranked by their active Phase 3 clinical pipeline, from ClinicalTrials.gov, alongside recent FDA drug recalls from openFDA. A large or growing late-stage pipeline is a forward catalyst; a recent Class I/II recall is a risk flag. 2 of these are also names the PriorMoves 13F model ranks. As of 2026-09-22.
Descriptive context, not a recommendation and not a return claim.
| # | Company | Active Phase 3 | Recent recalls | Worst class | On model board |
|---|---|---|---|---|---|
| 1 | MRK Merck | 140 | - | - | ○ |
| 2 | LLY Eli Lilly | 103 | - | - | ○ |
| 3 | JNJ Johnson & Johnson | 98 | - | - | ○ |
| 4 | PFE Pfizer | 95 | - | - | ○ |
| 5 | ABBV AbbVie | 76 | 1 | Class III | ● 70 |